CORT
Price
$79.37
Change
-$4.44 (-5.30%)
Updated
Apr 3 closing price
Capitalization
8.38B
26 days until earnings call
DNLI
Price
$12.79
Change
-$0.95 (-6.91%)
Updated
Apr 3 closing price
Capitalization
1.86B
39 days until earnings call
Ad is loading...

CORT vs DNLI

Header iconCORT vs DNLI Comparison
Open Charts CORT vs DNLIBanner chart's image
Corcept Therapeutics
Price$79.37
Change-$4.44 (-5.30%)
Volume$2.09M
Capitalization8.38B
Denali Therapeutics
Price$12.79
Change-$0.95 (-6.91%)
Volume$1.52M
Capitalization1.86B
CORT vs DNLI Comparison Chart
Loading...
CORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CORT vs. DNLI commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CORT is a Hold and DNLI is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (CORT: $79.37 vs. DNLI: $12.79)
Brand notoriety: CORT and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CORT: 135% vs. DNLI: 123%
Market capitalization -- CORT: $8.38B vs. DNLI: $1.86B
CORT [@Biotechnology] is valued at $8.38B. DNLI’s [@Biotechnology] market capitalization is $1.86B. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CORT’s FA Score shows that 2 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • CORT’s FA Score: 2 green, 3 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, CORT is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CORT’s TA Score shows that 6 TA indicator(s) are bullish while DNLI’s TA Score has 5 bullish TA indicator(s).

  • CORT’s TA Score: 6 bullish, 4 bearish.
  • DNLI’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both CORT and DNLI are a good buy in the short-term.

Price Growth

CORT (@Biotechnology) experienced а +40.03% price change this week, while DNLI (@Biotechnology) price change was -9.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.89%. For the same industry, the average monthly price growth was -11.08%, and the average quarterly price growth was -14.87%.

Reported Earning Dates

CORT is expected to report earnings on Apr 30, 2025.

DNLI is expected to report earnings on May 13, 2025.

Industries' Descriptions

@Biotechnology (-8.89% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CORT($8.38B) has a higher market cap than DNLI($1.86B). CORT YTD gains are higher at: 57.511 vs. DNLI (-37.242). CORT has higher annual earnings (EBITDA): 138M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. CORT (383M). CORT has less debt than DNLI: CORT (6.94M) vs DNLI (48.7M). CORT has higher revenues than DNLI: CORT (675M) vs DNLI (0).
CORTDNLICORT / DNLI
Capitalization8.38B1.86B451%
EBITDA138M-492.89M-28%
Gain YTD57.511-37.242-154%
P/E Ratio64.59N/A-
Revenue675M0-
Total Cash383M832M46%
Total Debt6.94M48.7M14%
FUNDAMENTALS RATINGS
CORT vs DNLI: Fundamental Ratings
CORT
DNLI
OUTLOOK RATING
1..100
8769
VALUATION
overvalued / fair valued / undervalued
1..100
84
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
14100
SMR RATING
1..100
4095
PRICE GROWTH RATING
1..100
3588
P/E GROWTH RATING
1..100
598
SEASONALITY SCORE
1..100
4650

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CORT's Valuation (84) in the Pharmaceuticals Other industry is in the same range as DNLI (94) in the Biotechnology industry. This means that CORT’s stock grew similarly to DNLI’s over the last 12 months.

CORT's Profit vs Risk Rating (14) in the Pharmaceuticals Other industry is significantly better than the same rating for DNLI (100) in the Biotechnology industry. This means that CORT’s stock grew significantly faster than DNLI’s over the last 12 months.

CORT's SMR Rating (40) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (95) in the Biotechnology industry. This means that CORT’s stock grew somewhat faster than DNLI’s over the last 12 months.

CORT's Price Growth Rating (35) in the Pharmaceuticals Other industry is somewhat better than the same rating for DNLI (88) in the Biotechnology industry. This means that CORT’s stock grew somewhat faster than DNLI’s over the last 12 months.

CORT's P/E Growth Rating (5) in the Pharmaceuticals Other industry is significantly better than the same rating for DNLI (98) in the Biotechnology industry. This means that CORT’s stock grew significantly faster than DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CORTDNLI
RSI
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
69%
Bullish Trend 1 day ago
73%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 1 day ago
88%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 12 days ago
81%
Bullish Trend 8 days ago
79%
Declines
ODDS (%)
Bearish Trend 1 day ago
66%
Bearish Trend 4 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
70%
Bullish Trend 1 day ago
77%
Aroon
ODDS (%)
Bullish Trend 4 days ago
68%
Bearish Trend 1 day ago
83%
View a ticker or compare two or three
Ad is loading...
CORT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ALPCX10.54N/A
N/A
American Century Focused Lg Cap Val C
GSQRX30.81N/A
N/A
Goldman Sachs Small Cap Value R
MACEX12.86N/A
N/A
Martin Currie Emerging Markets A
TRHZX149.08N/A
N/A
T. Rowe Price Equity Index 500 Z
MIIOX25.32N/A
N/A
Marsico International Opportunities Inst

CORT and

Correlation & Price change

A.I.dvisor indicates that over the last year, CORT has been loosely correlated with TENX. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CORT jumps, then TENX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CORT
1D Price
Change %
CORT100%
-5.30%
TENX - CORT
41%
Loosely correlated
-4.76%
FHTX - CORT
41%
Loosely correlated
-7.89%
AGIO - CORT
41%
Loosely correlated
-2.57%
DNLI - CORT
40%
Loosely correlated
-6.91%
ARCT - CORT
37%
Loosely correlated
-7.01%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-6.91%
BEAM - DNLI
57%
Loosely correlated
-10.93%
ARWR - DNLI
56%
Loosely correlated
-4.96%
NTLA - DNLI
55%
Loosely correlated
-5.62%
RCKT - DNLI
54%
Loosely correlated
-11.75%
CRSP - DNLI
53%
Loosely correlated
-4.47%
More